皇冠体育app

New regulatory recognition routes for medicines will be established using approvals from Australia, Canada, the European Union, Japan, Switzerland, Singapore and the United States, the Medicines and Healthcare products Regulatory Agency has announced today.

This means that patients will have access to safe and effective medicines that have been approved by trusted regulatory partners in other countries. 皇冠体育app new international recognition routes will sit alongside the MHRA鈥檚 own unique innovation pathway for medicines which integrates early regulatory advice with health technology assessment advice.

皇冠体育appse recognition routes, which have been facilitated by existing international partnerships such as those developed through the Access Consortium and Project Orbis, mark the start of a new international recognition framework for medicines that will be in place by the first quarter聽of 2024.

皇冠体育app new framework will allow the MHRA to聽make the most of the expertise and decision-making of trusted regulatory partners to streamline assessments of specific products.聽As a result, cutting-edge medicines that have been approved in other countries will get to UK patients more quickly, with cost reductions and streamlined regulatory processes for聽industry.

As a sovereign regulator, the UK聽regulator will still be responsible for approving all 鈥榬ecognition route鈥� applications under the new framework, ensuring that all products are safe and of sufficient quality to be licensed in the UK. 皇冠体育app MHRA will maintain rigorous scrutiny and retain the authority聽to聽reject applications if the evidence provided聽is considered insufficiently robust.

At the time of the UK鈥檚 exit from the European Union, the MHRA introduced temporary routes to market for European approved products in Great Britain, known as EU 鈥榬eliance鈥� routes, to ensure that patients could continue to have timely access to new treatments. 皇冠体育appse temporary routes are due to expire at the end of 2023.

While the international recognition routes announced today focus on medicines, work is underway to establish similar routes for medical devices. As part of this ongoing work, the MHRA will launch a new targeted consultation on medical devices that will gather views on a wide range of topics, including recognising conformity assessments or approvals from international regulatory partners.

Dr June Raine, MHRA Chief Executive, said:

We are focused on providing UK patients faster access to the absolute best, most cutting-edge, and safest medical treatments. By fast-tracking access to approved products from other countries, we鈥檙e ensuring that innovative healthcare solutions reach those in need without delay.

皇冠体育app introduction of the new routes will complement the work being done through the MHRA鈥檚 Innovative Licensing and Access Pathway (ILAP), establishing an additional avenue for accelerated access to life-saving new medicines. Combining MHRA鈥檚 globally recognised high standards with improved flexibility and a sustained collaborative approach across the healthcare system, the ILAP is helping reduce the time to market for innovative treatments by developing medicines that are both regulatory and access ready.

Through this new dual approach, we will聽contribute to the UK鈥檚 ambition to be a global science superpower, by making the UK one of the聽best places in the world to bring life-changing healthcare products to patients safely.

A 拢10m funding from HM Treasury was announced earlier this year to support the development of this new recognition framework.

Find out more

Follow us on Twitter:

Follow us on LinkedIn:

Notes to editors

1. 皇冠体育app Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for regulating all medicines and medical devices in the UK by ensuring they work and are acceptably safe.聽 All our work is underpinned by robust and fact-based judgements to ensure that the benefits justify any risks.

2. 皇冠体育app MHRA is an executive agency of the Department of Health and Social Care.

3. For media enquiries, please contact the [email protected].